MITOMYCIN FOR INJECTION
As listed in the register: MITOMYCIN FOR INJECTION
20 mg · powder for solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Mitomycin
- Made by
- Teva Canada Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (JELMYTO). It describes the substance, not this exact product.
Mitomycin inhibits the synthesis of deoxyribonucleic acid (DNA).
The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking.
Mitomycin is metabolized primarily in the liver, but metabolism occurs in other tissues as well.
Mitomycin is eliminated unchanged in the urine.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-07-09
Safety of the active substance
From the US prescribing label for the same active substance (JELMYTO). It describes the substance, not this exact product.
- JELMYTO is contraindicated in patients with perforation of the bladder or upper urinary tract.
- Perforation of the bladder or upper urinary tract.
The most common adverse reactions (≥ 20%) reported were ureteric obstruction, flank pain, urinary tract infection, hematuria, renal dysfunction, nausea, abdominal pain, fatigue, dysuria, and vomiting.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Teva Canada Limited |
|---|---|
| Active substance | Mitomycin |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 20 mg |
| Form | powder for solution |
| Classification | L01DC03 · Cancer treatments and immune-system medicines |
| Route | intravenous, intravesical |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02230451 |
| DPD drug code | 49400 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- powder for solution3 products
20 mg3
20 mg · 3 companies
- Eugia Pharma Inc.
- Hikma Canada Limited
- Teva Canada Limited · this page
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.